Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic LeukemiaGlobeNewsWire · 3 days ago
Financial Contrast: Monte Rosa Therapeutics (NASDAQ:GLUE) & Cardiff Oncology (NASDAQ:CRDF)Defense World · Sep 21, 2026
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License AgreementGlobeNewsWire · Sep 14, 2026
Cardiff Oncology to Participate in September 2026 ConferencesGlobeNewsWire · Sep 2, 2026
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business UpdateGlobeNewsWire · Aug 11, 2026Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.12 | -$0.14 | Miss |
| May 14, 2026 | -$0.13 | -$0.18 | Miss |
| Feb 24, 2026 | -$0.18 | -$0.11 | Beat |
| Nov 6, 2025 | -$0.20 | -$0.17 | Beat |
| Jul 29, 2025 | -$0.19 | -$0.21 | Miss |
| May 8, 2025 | -$0.19 | -$0.20 | Miss |